Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

Data ReadoutpositiveBempikibartPositive

AI Analysis

Summary

Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA trial of Bempikibart in alopecia areata, with clinically meaningful efficacy on the primary endpoint showing a 35.3% mean reduction in SALT score and 40.0% of patients achieving SALT-20 response.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

36-week topline results from Part B of SIGNAL-AA trial showed mean percent reduction in SALT score of 35.3% from baseline in mITT analysis; 40.0% of patients achieved SALT-20 response at Week 36

Importance:6/10

Sentiment:

0.85

clinical trialefficacy dataalopecia areataPhase 2positive results

Read the original article

Published by PR Newswire Biotech on July 13, 2026 10:59 AM

Read Original